Saixing Acquires Lisapharma Business Unit Amidst Restructuring
Deal News | Jun 23, 2025 | Finance Community IT - 3 Private Equity
Saixing, a global investor based in China specializing in medical devices and healthcare services, has acquired a division of Lisapharma as part of its indirect company restructuring strategy initiated in late July 2024. The acquired division includes a production facility for sterile injectable medicines and a portfolio of industrial, technological, and intangible assets, secured through a public competitive bidding procedure by a Saixing group subsidiary. Advisors involved assisted Lisapharma in financial aspects, potential buyer search, and auction preparedness, while tax issues were managed by associate Amela Dzafic. Legal advisement for Lisapharma was provided by the firm Bird & Bird, and for Saixing, by Chiomenti. This transaction was finalized on June 6, 2025, encompassing the transfer of the industrial site in Erba, machinery, patents, certifications, market authorizations, some inventory, and all 78 employees to ensure operational continuity and leverage existing expertise. This acquisition not only maintains business and employment continuity for a historic Italian pharmaceutical company but also marks the beginning of new investment phases and developments aimed at strengthening its international market presence and enhancing its specialized skills.
Sectors
- Pharmaceuticals
- Private Equity
- Healthcare Services
Geography
- China – Saixing, the acquiring company, is a global investor based in China.
- Italy – Lisapharma, the target company, is an Italian pharmaceutical company, and the transaction involves an operational facility located in Erba, Italy.
Industry
- Pharmaceuticals – The article discusses the acquisition of a business unit within the pharmaceutical sector, involving sterile injectable medicines and related industry assets.
- Private Equity – Saixing, a private equity firm, is involved in acquiring a division of Lisapharma, highlighting investment activities in restructuring processes.
- Healthcare Services – Saixing specializes in healthcare services, and the acquisition aligns with its strategic interest in expanding within the medical devices and healthcare services sector.
Financials
- Not disclosed – The financial terms of the acquisition were not disclosed in the article.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Saixing | Acquirer | Company | A primary global investor based in China, active in medical devices and healthcare services. |
| Lisapharma | Target Company | Company | An Italian pharmaceutical company undergoing restructuring proceedings as part of a concordato preventivo in continuità aziendale indiretta. |
| Bird & Bird | Legal Advisor to Lisapharma | Company | A legal firm providing advisement to Lisapharma during the transaction. |
| Chiomenti | Legal Advisor to Saixing | Company | A legal advisory firm assisting Saixing with legal aspects of the acquisition. |
| Studio Bogoni | Financial Advisor to Lisapharma | Company | Provided financial advisory services to Lisapharma, handling financial aspects and preparing for the auction. |